Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 9, 2011 (rev. 1)


Steven Smith has been selected to serve as the executive vice president of bioinformatics at Orion Genomics.

Smith will lead Orion's efforts to develop bioinformatics tools that support its diagnostics and genomics services business units. Furthermore, he will direct the development of bioinformatics infrastructure to support new programs that use next-generation sequencing for high-resolution mapping of DNA methylation.

Prior to joining Orion, Smith was vice president of bioinformatics at NimbleGen (now part of Roche), where he led the development of bioinformatics tools for making custom arrays. He also worked at Millipore, Genetics Computer Group, and owned Genesmith Informatics, a consulting firm that specialized in bioinformatics support, software development, and genome analysis.

Smith served as the director of computation at the Harvard Genome Laboratory where he led the assembly and analysis of the Mycoplasma capricolum genome. He holds a BS in computer science engineering from the University of Illinois at Urbana-Champaign's school of engineering.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.